Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation.

Publication Type:

Journal Article


Transplantation, Volume 89, Issue 11, p.1336-40 (2010)


2010, Animals, Antibodies, Monoclonal, Antigens, CD45, Biologics Production Core Facility, Bismuth, Center-Authored Paper, Clinical Research Division, Comparative Medicine Core Facility, Culture Media, Conditioned, Dogs, Experimental Histopathology Core Facility, Flow Cytometry Core Facility, Graft Survival, Haploidy, hematopoietic stem cell transplantation, Neutrophils, Radioisotopes, Research Trials Office Core Facility - Biostatistics Service, Shared Resources, Thrombocytopenia, Transplantation, Homologous


A pilot study was conducted to determine whether conditioning using selective targeting of hematopoietic cells with an alpha-particle emitter, bismuth-213 ((213)Bi)-labeled anti-CD45 monoclonal antibody (mAb) is sufficient to overcome the major histocompatibility barrier in a canine model of dog leukocyte antigen-haploidentical hematopoietic cell transplantation (HCT).